European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Cardiac sympathetic nerve activity in the non-culprit lesion predicts poor prognosis in patients with STEMI","authors":"Takumi Kondo,Takahisa Yamada,Mitsutoshi Asai,Takashi Morita,Masato Kawasaki,Atsushi Kikuchi,Tsutomu Kawai,Masahiro Seo,Jun Nakamura,Takeshi Fujita,Yuki Kokubu,Fumiya Oyama,Hidekazu Obayashi,Hikaru Kurihara,Kenji Noda,Natsuki Nishikawa,Ayami Suganami,Masaaki Takahashi,Yasushi Sakata,Masatake Fukunami","doi":"10.1007/s00259-026-08186-6","DOIUrl":"https://doi.org/10.1007/s00259-026-08186-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"17 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of quantitative myocardial blood flow and flow reserve by dynamic CZT-SPECT for major adverse cardiovascular events","authors":"Yu-Cheng Shih,Shan-Ying Wang,Yu-Chien Shiau,Yen-Wen Wu","doi":"10.1007/s00259-026-08195-5","DOIUrl":"https://doi.org/10.1007/s00259-026-08195-5","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"17 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colonic metastasis from anaplastic thyroid carcinoma: The value of [¹⁸F]FDG PET/CT in an unusual presentation.","authors":"Marta Argelés Colet, Viviana Carrero Vasquez, María Pilar Perlaza Jimenez, Elena Llinares Tello, Alba Rodríguez Gasen, Andrea Isidora Fritsch Medina, Montserrat Cortés Romera","doi":"10.1007/s00259-026-08193-7","DOIUrl":"https://doi.org/10.1007/s00259-026-08193-7","url":null,"abstract":"<p><p>Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy associated with poor survival and a metastatic pattern that typically involves the lungs. A patient with ATC harboring a papillary component and a BRAF V600E mutation, with locoregional invasion, was treated with surgery and radiotherapy following detection of residual disease. After a disease-free interval of 17 months, a lesion was identified at the splenic flexure of the colon, which was histologically confirmed as a metastasis from ATC. This case demonstrates an unusual metastatic site and emphasizes the value of [¹⁸F]FDG PET/CT in detecting atypical recurrences.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging tracers targeting c-MET: a systematic review of preclinical evidence and clinical translation.","authors":"Rick W A Verdijk, Stevie M van der Mierde, Nataliia Berehova, Maarten P van Meerbeek, Oscar R Brouwer, Henk G van der Poel, Fijs W B van Leeuwen, Tessa Buckle","doi":"10.1007/s00259-026-08174-w","DOIUrl":"https://doi.org/10.1007/s00259-026-08174-w","url":null,"abstract":"<p><strong>Introduction: </strong>The mesenchymal-epithelial transition factor (c-MET) is an emerging target for molecular imaging owing to its widespread overexpression across multiple cancer types. This systematic review evaluated radioactive and fluorescent c-MET-targeting tracers in preclinical and clinical studies, focussing on their translational potential and imaging performance.</p><p><strong>Methods: </strong>This systematic review was conducted according to PRISMA 2020 guidelines. A PubMed, Embase, and Scopus search for studies evaluating radioactive or fluorescent c-MET-targeting tracers was complemented with expert-suggested reports. Tracer characteristics, imaging performance, and safety data were extracted.</p><p><strong>Results: </strong>Fifty preclinical and thirteen clinical reports were included, comprising 62 distinct c-MET-targeting tracers across several compound classes. Only four peptide-based tracers progressed to clinical evaluation: the fluorescent tracers EMI-137 and cMBP-ICG, and the PET tracers ⁶⁸Ga-EMP-100 and ⁶⁸Ga-MetP. EMI-137 (8 studies) enabled fluorescence-guided tumour visualisation (tumour-to-background ratios; TBRs 1.3-9.7) and identified additional malignant lesions in selected applications. Although tracer uptake generally corresponded with c-MET expression, diagnostic performance was limited by uptake in benign c-MET-expressing tissues, yielding a sample-size weighted average sensitivity and specificity of 81.7% and 39.3%. cMBP-ICG (2 studies), evaluated exclusively in oral cavity cancer, demonstrated improved discrimination between malignant and benign tissue and outperformed conventional assessment for biopsy-site selection, reporting TBRs of 2.7-4.1 and a weighted average sensitivity and specificity of 85.5% and 91.1%. The PET tracers ⁶⁸Ga-EMP-100 (2 studies) and ⁶⁸Ga-MetP (1 study) demonstrated feasibility for whole-body c-MET PET imaging, with the latter additionally showing a positive correlation between tumour uptake and immunohistochemical c-MET expression. All four tracers showed favourable safety, with only mild adverse events reported. CONCLUSIONTARGETING TRACER PIPELINE.</p><p><strong>Numbers represent distinct: </strong>Despite extensive preclinical development, only four peptide-based tracers have progressed to clinical evaluation. Clinical evidence supports the feasibility of c-MET-targeted molecular imaging but remains limited by methodological heterogeneity, small sample sizes, limited biological validation, and variable diagnostic performance. Larger, standardised studies are needed to establish the added clinical value and broader applicability of c-MET-targeting tracers in molecular imaging.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma.","authors":"Leonie Hoermann, Fatma Burcu Seker, Emanuel Joseph, Sabrina V Kirchleitner, Jens Blobner, Lea H Kunze, Justus F Thevis, Selina Hummel, Amelie L Englert, Karin Wind-Mark, Adrien Holzgreve, Simon Lindner, Rudolf A Werner, Louisa von Baumgarten, Nathalie L Albert, Nikolaus Plesnila, Matthias Brendel, Laura M Bartos","doi":"10.1007/s00259-026-08187-5","DOIUrl":"https://doi.org/10.1007/s00259-026-08187-5","url":null,"abstract":"<p><strong>Background: </strong>Translocator protein (TSPO)-PET imaging facilitates monitoring of glioblastoma in preclinical models and patients. However, specificity of TSPO-PET signals remains to be investigated. In this study, we aimed to decipher exact contributions of cellular and extracellular compartments including the impact of blood-brain barrier (BBB) disruption to TSPO-PET signals in an experimental glioblastoma mouse model.</p><p><strong>Methods: </strong>Mice with implanted glioblastoma (SB28; n = 36 early-stage, n = 39 late-stage; GFP(+)) were injected with the TSPO tracer [¹⁸F]GE-180 (21 MBq ± 1.5 MBq). Dynamic 60 min microPET scans were performed with and without prior blocking by excessive cold radiotracer. Tumors were dissociated, followed by cell sorting of tumor cells, tumor-associated microglia/macrophages (TAMs, CD11b(+)) and non-tumor/non-TAM (i.e. remaining) cells with subsequent gamma emission measures and flow cytometry (scRadiotracing) to calculate radioactivity per single cell. PET signals and single-cell tracer uptake in tumors and non-lesional hemispheres were compared between blocked and unblocked conditions. N = 10 mice were intravenously injected with fluorescent Dextran to investigate BBB disruption by confocal microscopy in correlation with TSPO-PET signals of the same animals.</p><p><strong>Results: </strong>TSPO-PET indicated strong but incomplete signal reduction after blocking in tumors (early-stage: -72%; late-stage: -59%, p < 0.001) and contralateral hemispheres (early stage: -65%, late-stage: -63%, p < 0.001) compared to unblocked animals. We found nearly complete blocking of radiotracer uptake across all analyzed cell fractions (tumor cells: -95%, p = 0.0039; TAMs: -98%, p < 0.0001; remaining cells: -99%, p = 0.0033) compared to unblocked mice, regardless of tumor stages. There was a significant correlation of PET signal reduction (R=-0.824, p = 0.0034) as well as residual PET signal upon blocking (R = 0.809, p = 0.0046) with Dextran intensity.</p><p><strong>Conclusion: </strong>Specificity of TSPO-PET signals in experimental glioblastoma reaches 72% in early-stage tumors, but decreases to 59% in late-stage SB28 tumors, due to progressive contributions of BBB disruption. Non-specific TSPO tracer uptake is driven by BBB disruption and fully allocated to the extracellular compartment, whereas cellular TSPO tracer uptake shows strong specificity.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach.","authors":"Haluk Burcak Sayman, Omer Aras, Muhammed Veysel Hekim, Kerem Sağlam, Elife Akgün, Fazilet Öner Dinçbaş","doi":"10.1007/s00259-026-08194-6","DOIUrl":"https://doi.org/10.1007/s00259-026-08194-6","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility, safety, and preliminary efficacy of systemic targeted alpha therapy with [²²⁵Ac]-PSMA in patients with recurrent high-grade glioma (HGG). Glioblastoma multiforme (GBM) and HGGs are highly aggressive primary brain tumors with limited treatment options at recurrence. Expression of prostate-specific membrane antigen (PSMA) in the neovasculature of GBM provides a promising target for radioligand therapy using alpha emitters such as Actinium-225.</p><p><strong>Methods: </strong>Four patients with histologically confirmed recurrent HGG received [²²⁵Ac]-PSMA therapy at a dose of 100 kBq/kg per cycle. Diagnoses were established according to the WHO classification available at the time of diagnosis. The cohort included three patients with GBM and one patient with a high-grade diffuse glial tumor, WHO grade III. Treatment cycles were intended at 8-12-week intervals. Baseline and follow-up assessments were performed visually and then semi-quantitave parameters were described on [⁶⁸Ga]-PSMA PET/MRI or PET/CT images also using contrast-enhanced MRI. Clinical status and hematologic parameters were monitored throughout therapy and follow-up.</p><p><strong>Results: </strong>While every patient ultimately developed progressive disease following treatment, the predefined PSMA-avid index lesion regressed in one patient and remained stable in another. No grade ≥ 3 adverse events attributable to [²²⁵Ac]-PSMA or treatment-related mortality were observed. Low-grade toxicity was limited and mainly consisted of mild xerostomia.</p><p><strong>Conclusion: </strong>Systemic [²²⁵Ac]-PSMA therapy appeared feasible and well tolerated, showing preliminary evidence of disease control in recurrent HGGs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of [¹⁸F]AlF-NOTA-JR11 PET/MR and [⁶⁸Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.","authors":"Xiao Jin, Qing Xie, Xiangxiang Ding, Boqi Yu, Yan Zhang, Xiaofan Su, Chunhui Yuan, Ming Lu, Zhi Yang, Jiangyuan Yu","doi":"10.1007/s00259-026-08176-8","DOIUrl":"https://doi.org/10.1007/s00259-026-08176-8","url":null,"abstract":"<p><strong>Purpose: </strong>To compare [¹⁸F] AlF-NOTA-JR11 PET/MR and [⁶⁸Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors (NETs).</p><p><strong>Methods: </strong>Forty-one patients with biopsy-proven NETs were enrolled and underwent [⁶⁸Ga]Ga-DOTA-TATE PET/CT and [¹⁸F] AlF-NOTA-JR11 PET/MR. Physiological organ uptake, lesion number, maximum standardized uptake value (SUV_max) and tumor-to-background ratio (TBR) were compared between the two examinations.</p><p><strong>Results: </strong>[¹⁸F] AlF-NOTA-JR11 PET/MR and [⁶⁸Ga]Ga-DOTA-TATE PET/CT depicted 924 and 580 lesions, respectively (p < 0.001).These included 754 and 405 liver metastases(p < 0.001), as well as 29 and 25 primary tumors (p = 0.125), respectively. The 405 liver metastases detected by both examinations were significantly larger than the 349 lesions detected only by [¹⁸F]AlF-NOTA-JR11 [median diameter, 14.00 mm (Q1, Q3: 10.00, 21,00) vs. 6.00 mm (Q1, Q3: 5.00, 9.00); p < 0.001]. No significant differences were found for the detection of lymph node metastases (p = 1.000) or bone metastases (p = 0.188). In the patient-based comparison, 76% of patients (31/41) had more lesions detected by [¹⁸F]AlF-NOTA-JR11 PET/MR than by [⁶⁸Ga]Ga-DOTA-TATE PET/CT. Lesion SUV_max for [¹⁸F]AlF-NOTA-JR11 was significantly lower than that for [⁶⁸Ga]Ga-DOTA-TATE in primary tumors (p = 0.002), liver metastases (p = 0.017) and bone metastases (p = 0.008), whereas no significant difference was observed in lymph node metastases (p = 0.144). [¹⁸F]AlF-NOTA-JR11 PET/MR showed higher TBR than [⁶⁸Ga]Ga-DOTA-TATE PET/CT in primary tumors (p = 0.014), lymph node metastases (p = 0.034) and liver metastases (p < 0.001), with no significant difference in bone metastases(p = 0.343).</p><p><strong>Conclusion: </strong>[¹⁸F]AlF-NOTA-JR11 PET/MR shows lower background uptake and higher TBR for primary tumors, lymph node metastases and liver metastases. It also detected more liver metastases than [⁶⁸Ga]Ga-DOTA-TATE PET/CT. These findings provide valuable evidence supporting the clinical use of [¹⁸F]AlF-NOTA-JR11 PET/MR in patients with NETs.</p><p><strong>Trial registration number: </strong>2020KT15 DATE OF REGISTRATION: 30/03/2020.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.","authors":"Farid Gossili, Frederik Harving, Astrid Christine Petersen, Claus Madsen, Kirsten Bouchelouche, Niels Henrik Bruun, Robert Johannes Leusink, Ayesha Ahmed, Anja Morratz Laursen, Helle D Zacho","doi":"10.1007/s00259-026-08191-9","DOIUrl":"https://doi.org/10.1007/s00259-026-08191-9","url":null,"abstract":"<p><strong>Purpose: </strong>Prostate-specific membrane antigen (PSMA) PET has emerged as a sensitive imaging modality for prostate cancer (PC), but its role in intraprostatic tumour localisation relative to multiparametric MRI (mpMRI) and differences between [¹⁸F]- and [⁶⁸Ga]-PSMA ligands remain unclear. This study compared the diagnostic performance of [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT, and mpMRI for intraprostatic tumour localisation and detection of clinically significant prostate cancer (csPC).</p><p><strong>Methods: </strong>In this prospective single-centre study, patients with biopsy-proven high-risk PC undergoing radical prostatectomy were recruited. All patients underwent [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT. Following a protocol amendment, mpMRI was added as a secondary exploratory imaging modality and performed in a subset of patients prior to surgery. Histopathology was the reference standard; csPC was defined as ≥ISUP3 or ISUP2 with tertiary Gleason 5 pattern. Diagnostic performance was assessed on a per-patient and per-region basis, dividing the prostate into sextants and using mixed regression models to account for clustering. Secondary analyses evaluated the detection of pathological features beyond the prostate, including extraprostatic extension (EPE) and seminal vesicle invasion (SVI).</p><p><strong>Results: </strong>Fifty patients were included in the analysis of PSMA PET/CT, and 45 patients had mpMRI. At the patient level, [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT and mpMRI demonstrated sensitivities of 98%, 100%, and 96%, respectively, for the detection of csPC, with corresponding diagnostic accuracies of 96%, 98%, and 93%, respectively. Of 300 sextants, 205 contained csPC. [¹⁸F]F-PSMA-1007 PET/CT identified csPC in 143/300 sextants (accuracy: 69.8%, 95%CI 64.0-75.6). [⁶⁸Ga]Ga-PSMA-11 PET/CT detected csPC in 136/300 sextants (accuracy: 67.8%, 95%CI 62.3-73.4). mpMRI identified csPC in 89/270 sextants (accuracy: 62.9%, 95%CI 56.3-69.4). PSMA PET ligands showed significantly higher sensitivity than mpMRI (p < 0.001), whereas mpMRI demonstrated higher specificity (p = 0.002). No significant differences were observed between [¹⁸F]F-PSMA-1007 and [⁶⁸Ga]Ga-PSMA-11. Detection of pathological features of local tumour extension was limited across all modalities. Sensitivity for EPE was 12%, 23%, and 9%, and sensitivity for SVI was 30%, 30%, and 14% for [¹⁸F]F-PSMA-1007 PET/CT, [⁶⁸Ga]Ga-PSMA-11 PET/CT, and mpMRI, respectively.</p><p><strong>Conclusion: </strong>PSMA PET/CT ligands provide higher sensitivity than mpMRI for intraprostatic tumour localisation, while no statistically significant differences in diagnostic performance were detected between [¹⁸F]- and [⁶⁸Ga]-PSMA ligands in this cohort. These findings support the potential complementary role of PSMA PET and mpMRI for preoperative intraprostatic tumour localisation in high-risk PC.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study.","authors":"Yong Liao, Xin Huang, Ziwei Liang, Junpeng Ma, Xiaobin Feng, Wenkang Fu, Bin Liang, Shizhong Yang, Guangxin Li, Lei Bao, Tiantian Zhang, Linxia Zheng, Can Liu, Mulan Tang, Lin Zhang, Jiahong Dong","doi":"10.1007/s00259-026-08170-0","DOIUrl":"https://doi.org/10.1007/s00259-026-08170-0","url":null,"abstract":"<p><strong>Objective: </strong>Extrahepatic collateral supply from the inferior phrenic artery (IPA) is frequently observed in patients with hepatocellular carcinoma (HCC) undergoing yttrium-90 selective internal radiation therapy (⁹⁰Y-SIRT). Currently, no standardized IPA management algorithm has been established. This study aimed to propose stratified interventional strategies for IPA and compare the safety and oncological outcomes between two mainstream approaches.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 290 consecutive unresectable HCC patients treated with ⁹⁰Y-SIRT between October 2022 and December 2025. Patients with suspected IPA tumor perfusion on pre-treatment cross-sectional imaging were enrolled. All patients underwent superselective IPA catheterization under combined digital subtraction angiography (DSA) and cone-beam computed tomography (CBCT). According to tumor volume and anatomical characteristics of non-target vessels, patients were divided into direct Y-90 infusion group and IPA embolization group. Tumor response and treatment-related adverse events were assessed and compared.</p><p><strong>Results: </strong>A total of 78 patients with angiographically confirmed IPA tumor supply were finally enrolled, including 45 patients in the IPA Y-90 infusion group and 33 in the IPA embolization group. The median administered radioactivity via IPA was 0.3 GBq. Based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), the objective response rates (ORRs) at 1 and 3 months were 60.0% and 82.3% in the infusion group, versus 48.5% and 69.7% in the embolization group. The compensatory distribution rate of Y-90 microspheres in the original IPA-perfused regions reached approximately 88.0% after IPA embolization. Only mild, reversible thoracic adverse events were noted in both groups, with no severe treatment-related complications.</p><p><strong>Conclusion: </strong>DSA-CBCT combined evaluation is essential for pre-procedural IPA anatomical assessment. Direct Y-90 microsphere infusion via IPA yields superior tumor control when non-target vessels are manageable and IPA-perfused tumor volume ≥ 20 mL. IPA embolization is a reliable alternative for patients with untreatable non-target branches or tumor volume < 20 mL. Both strategies demonstrate favorable safety profiles. The proposed stratified algorithm represents a preliminary approach that warrants further external validation for IPA management during ⁹⁰Y-SIRT for HCC.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility.","authors":"Keiko Akashi, Maryam Shahi, Ceylan Colak, Tatnai L Burnett, David J Bartlett, Annie T Packard, Wendaline M VanBuren, Hiroaki Takahashi","doi":"10.1007/s00259-026-08189-3","DOIUrl":"https://doi.org/10.1007/s00259-026-08189-3","url":null,"abstract":"<p><strong>Purpose: </strong>Fibroblast activation protein (FAP) is expressed in the fibroinflammatory stroma of endometriosis, but its relationship to conventional imaging visibility is unknown. We evaluated FAP expression in deep endometriosis (DE) and superficial endometriosis (SE) and its relationship to lesion visibility on magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS).</p><p><strong>Methods: </strong>We retrospectively analyzed specimens from DE (n = 13) and SE (n = 9) patients who underwent MRI and/or TVUS. FAP expression was assessed immunohistochemically using H-scores. Two abdominal radiologists independently graded the visibility of pathology-confirmed lesions on MRI and TVUS using a study-specific 0-3 scale, with N/A assigned when the lesion location was outside the available imaging field of view. H-scores were compared by phenotype and imaging visibility (lower [0-1] vs higher [2-3]) using nonparametric analyses.</p><p><strong>Results: </strong>FAP expression did not differ significantly between DE and SE (median H-scores 170 vs 200, p= 0.738). Endometriosis showed substantial FAP expression, although H-scores were lower than colorectal adenocarcinoma controls (p < 0.05). On MRI, no lesions were assigned N/A; low-/high-visibility groups included 5/16 lesions for Reader 1 and 3/18 for Reader 2, with median H-scores of 220/170 for both readers (both p > 0.05). On TVUS, 1 and 2 lesions were assigned N/A for Readers 1 and 2, respectively; among evaluable lesions, low-/high-visibility groups included 2/10 and 1/10 lesions, with median H-scores of 48/165 and 20/160, respectively, limiting conclusions regarding visibility and FAP expression.</p><p><strong>Conclusion: </strong>DE and SE showed substantial stromal FAP expression, including SE lesions poorly visible on conventional imaging. These findings provide a histopathological rationale for FAP-targeted imaging in endometriosis.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}